1. Gallup Survey. Heartburn across Americ Princeton, NJ: Gallup Organization, 1998 Mar 24.
2. Harris Group. Feb. 5,2001. Proton Pump Inhibitor Use and Barriers to Successful Treatment. Harris Interactive/Acuity HealthGroup. Available at:
www.businesswire.com/
webbox/bw.020501/
210362364.htm.
Accessed Aug. 21, 2001.
3. Wilkins J, Heggers J, Willette R, Wilkins JS. Relief of heartburn naturally. Proprietary study. Wilkins Research, Galveston Texas.
4. Norris J, Ed. Gastroesophageal reflux. In: Professional Guide to Diseases. 5th ed. Springhouse, Pa: Springhouse Corporation, 1995: 660-663.
5. Porth CM. Gastroesophageal reflux. In: Pathophysiology: Concepts of Altered Health States. 5th ed. Philadelphia, Pa: Lippincott; 1998: 722-723.
6. Norris J, Ed. Peptic ulcers. In: Professional Guide to Diseases. 5th ed. Springhouse, Pa: Springhouse Corporation, 1995: 676-678.
7. Dajani EZ. Gastroesophageal reflux disease: pathophysiology and pharmacology overview. J Assoc Acad Minor Phys. 2000;11:7-11.
8. Bartlett DW, Evans DF, Smith BG. The relationship between gastroesophageal reflux disease and dental erosion. J Oral Rehabil. 1996;23:289-297.
9. Silva MA, Damante JH, Stipp AC, Tolentino MM, Carlotto PR, Fleury RN. Gastroesophageal reflux disease: New oral findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:301-10.
10. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett’s esophagus: a prospective controlled investigation. Am J Med. 2001;111:33-37.
11. El-Serag HB, Hepworth EJ, Lee P, Sonnenberg Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am J Gastroenterol. 2001;96:2013-2018.
12. Diener U, Patti MG, Molena D, Fisichella PM, Way LW. Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg. 2001;5:260-265.
13. Wetscher GJ, Glaser K, Gadenstaetter M, Profanter C, Hinder R The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. Am J Surg. 1999;177:189-192.
14. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson J Functional esophageal disorders. Gut. 1999;45:II31-1136.
15. Clark CS, Kraus BB, Sinclair J, Castell DO. Gastroesophageal reflux induced by exercise in healthy volunteers. JAM 1989;261:3599-3601.
16. National Digestive Diseases Information Clearinghouse. Gastroesophageal reflux disease. Available at: www.niddk.nih.gov/
health/digest/pubs/heartbrn/. Accessed Aug. 17, 2001.
17. Smit CF, Copper MP, van Leeuwen JA, Schoots IG, Stanojcic LD. Effect of cigarette smoking on gastropharyngeal and gastroesophageal reflux. Ann Otol Rhino Laryngol. 2001;110:190-193.
18. Kahrilas PJ. Cigarette smoking and gastroesophageal reflux disease. Dig Dis. 1992;10:61-71.
19. Fisher RS, Roberts GS, Grabowski CJ, Cohen S. Altered lower esophageal sphincter function during early pregnancy. Gastroenterology. 1978;74:1233-1237.
20. Olans LB, Wolf JL. Gastroesophageal reflux in pregnancy. Gastrointest Endosc Clin N Am. 1994;4:699-712.
21. Scott VF. Gastroesophageal reflux disease: diagnosis and management. J Assoc Acad Minor Phys. 2000;11:12-14.
22. Lehne R Antacids: adverse effects. In: Pharmacology for Nursing Care. 3rd ed. Philadelphia, Pa: W.B. Saunders; 1998: 783-784.
23. Young LE, Koda-Kimble M Drug interactions associated with antacids. In: Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver, Wash: Applied Therapeutics, Inc; 1995:chapter 23, page 9.
24. Koo, J., Marshall, D. L. & DePaola, Antacid increases survival of Vibrio vulnificus and Vibrio vulnificus phage in a gastrointestinal model. Appl Environ Microbiol. 2001;67: 2895 – 2902.
25. Waldrom HL, Brenna E, Kleveland PM, Sandvik AK, Syversen U. Review article: the use of gastric acid-inhibitory drugs – physiological and pathophysiological consideration. Aliment Pharmacol Ther. 1993;7:589-596.
26. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27-34.
27. Evanepoel P. Alteration in digestion and absorption of nutrients during profound acid suppression. Baillieres Best Pract Res Clin Gastroenterol. 2001;15:539-551.
28. Crowell PL, Elson CE, Bailey HH, Elegbede A, Haag JD, Gould MN. Human metabolism of the experimental cancer therapeutic agent d-limonene. Cancer Chemother Pharmacol. 1994;35(1):31-7.
29. Vigushin DM, Poon GK, Boddy A, et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol. 1998; 42:111-117.
30. Nakaizumi A, Baba M, Uehara H, Iishi H, Tatsuta M. d-Limonene inhibits N-nitrosobis (2-oxopropyl)amine induced hamster pancreatic carcinogenesis. Cancer Lett. 1997;117:99-103.
31. Kawamori T, Tanaka T, Hirose Y, Ohnishi M, Mori H. Inhibitory effects of d-limonene on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Carcinogenesis. 1996;17:369-372.
32. Giri RK, Parija T, Das BR. d-limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-jun and c-myc. Oncol Rep. 1999;6:1123-1127.
33. Yano H, Tatsuta M, Iishi H, Baba M, Sakai N, Uedo N. Attenuation by d-limonene of sodium chloride-enhanced gastric carcinogenesis induced by N-methyl N’-nitro-
N-nitrosoguanidine in Wistar rats. Int J Cancer. 1999; 82:665-668.
34. Uedo N, Tatsuta M, Iishi H, et al. Inhibition by D-limonene of gastric carcinogenesis induced by N-methyl-N’-nitro-
N-nitrosoguanidine in Wistar rats. Cancer Lett. 1999;137:131-6.
No comments:
Post a Comment